VERA THERAPEUTICS, INC.
VERALoading price...
Overview
Previous Close32.23
Open32.70
Ask38.43
Bid23.32
Day's Range29.67 - 32.76
52 Week Range19.07 - 56.05
PE Ratio(TTM)--
Market Cap2.15B
Volume4.91M
Avg. Volume1.71M
12 Months Earnings-299.62M
12 Months Revenue0.00
Profit/Loss
| PARTICULARS | TTM | 2025 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 315.47M | 315.47M | 236.05M | 167.17M | 102.01M | 90.90M |
| Profit after Tax (Net Income) | -299.62M | -299.62M | -218.28M | -152.15M | -95.99M | -89.06M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Brisbane, United States
Website: https://veratx.com
Founder, President, CEO & Director: Dr. Marshall W. Fordyce M.D.
Employees: 339
About Company:
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.